Bibliographie

[1] Abraham LM, Selva D, Casson R, Leibovitch I. Mitomycin : clinical applications in ophthalmic practice. Drugs 2006;66:321–40.

[2] Abraham LM, Selva D, Casson R, Leibovitch I. The clinical applications of fluorouracil in ophthalmic practice. Drugs 2007;67:237–55.

[3] Chui J, Di Girolamo N, Wakefield D, Coroneo MT. The pathogenesis of pterygium : current concepts and their therapeutic implications. Ocul Surf 2008;6.

[4] Touhami A, Di Pascuale MA, Kawatika T, et al. Characterisation of myofibroblasts in fibrovascular tissues of primary and recurrent pterygia. Br J Ophthalmol 2005;89:269–74.

[5] Bekibele CO, Ashaye A, Olusanya B, et al. 5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence. Int Ophthalmol 2012;32.

[6] Kaufman SC, Jacobs DS, Lee WB, et al. Options and adjuvants in surgery for pterygium : a report by the American Academy of Ophthalmology. Ophthalmology 2013;120:201–8.

[7] Fakhry MA. The use of mitomycin C with autologous limbal-conjunctival autograft transplantation for management of recurrent pterygium. Clin Ophthalmol Auckl NZ 2011;5:123–7.

[8] Frucht-Pery J, Raiskup F, Ilsar M, et al. Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence. Am J Ophthalmol 2006;141:1044–50.

[9] Wong VA, Law FC. Use of mitomycin C with conjunctival autograft in pterygium surgery in Asian-Canadians. Ophthalmology 1999;106:1512–5.

[10] Wagdy FM, Farahat HG, Ellakwa AF, Mandour SS. Evaluation of conjunctival autografting augmented with mitomycin C application versus ologen implantation in the surgical treatment of recurrent pterygium. J Ophthalmol 2021;2021:8820926.

[11] Young AL, Tam PMK, Leung GYS, et al. Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0.02 % mitomycin C in primary pterygium excision. Cornea 2009;28:166–9.

[12] Alsarhani W, Alshahrani S, Showail M, et al. Characteristics and recurrence of pterygium in Saudi Arabia : a single center study with a long follow-up. BMC Ophthalmol 2021;21:207.

[13] Aydin A, Aksoy Y, Unal MH, Ersanli D. Necrotizing scleritis after pterygium surgery using mitomycin C. J Fr Ophtalmol 2012;35:74–5.

[14] Tittler EH, Nguyen P, Rue KS, et al. Early surgical debridement in the management of infectious scleritis after pterygium excision. J Ophthalmic Inflamm Infect 2012;2:81–7.

[15] Bekibele CO, Baiyeroju AM, Olusanya BA, et al. Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft. Eye Lond Engl 2008;22:31–4.

[16] Said DG, Faraj LA, Elalfy MS, et al. Intra-lesional 5 fluorouracil for the management of recurrent pterygium. Eye 2013;27:1123–9.

[17] Bekibele CO, Sarimiye TF, Ogundipe A, Olaniyan S. 5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium. Eye 2016;30:515–21.

[18] Nuzzi R, Tridico F. How to minimize pterygium recurrence rates : clinical perspectives. Clin Ophthalmol Auckl NZ 2018;12:2347–62.

[19] García Tirado A, de Los Boto, Bueis A, Rivas Jara L. Ocular surface changes in recurrent pterygium cases post-operatively treated with 5-fluorouracil subconjunctival injections. Eur J Ophthalmol 2019;29:9–14.

[20] Malik S, Khan MS, Basit I. Comparison of primary versus recurrent pterygium after intralesional 5-Fluorouracil. JPMA J Pak Med Assoc 2016;66:559–62.

[21] Khokhar S, Soni A, SinghSethi H, et al. Combined surgery, cryotherapy, and mitomycin-C for recurrent ocular surface squamous neoplasia. Cornea 2002;21:189–91.

[22] Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 2006;90:819–22.

[23] Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol 2013;24:336–42.

[24] Parrozzani R, Frizziero L, Trainiti S, et al. Topical 1 % 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia : long-term study. Br J Ophthalmol 2017;101:1094–9.

[25] Höllhumer R, Williams S, Michelow P. Ocular surface squamous neoplasia : management and outcomes. Eye Lond Engl 2021;35:1562–73.

[26] Shields CL, Shields JA, Armstrong T. Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy. Am J Ophthalmol 2001;132:576–8.

[27] Pe'er J, Frucht-Pery J. The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C. Am J Ophthalmol 2005;139:229–34.

[28] Shields CL, Demirci H, Shields JA, Spanich C. Dramatic regression of conjunctival and corneal acquired melanosis with topical mitomycin C. Br J Ophthalmol 2002;86:244–5.

[29] Panda A, Pe'er J, Aggarwal A, et al. Effect of topical mitomycin C on corneal endothelium. Am J Ophthalmol 2008;145(4):635–8.

[30] Ayres BD, Rapuano CJ. Excimer laser phototherapeutic keratectomy. Ocul Surf 2006;4:196–206.

[31] Dinh R, Rapuano CJ, Cohen EJ, Laibson PR. Recurrence of corneal dystrophy after excimer laser phototherapeutic keratectomy. Ophthalmology 1999;106:1490–7.

[32] Reddy JC, Rapuano CJ, Nagra PK, Hammersmith KM. Excimer laser phototherapeutic keratectomy in eyes with corneal stromal dystrophies with and without a corneal graft. Am J Ophthalmol 2013;155:1111–1118.e2.

[33] Gabison EE, Huet E, Baudouin C, Menashi S. Direct epithelial-stromal interaction in corneal wound healing : Role of EMMPRIN/CD147 in MMPs induction and beyond. Prog Retin Eye Res 2009;28:19–33.

[34] de Benito-Llopis L, Teus MA. Efficacy of surface ablation retreatments using mitomycin C. Am J Ophthalmol 2010;150(3):376–380.e2.

[35] Netto MV, Mohan RR, Ambrosio RJ, et al. Wound healing in the cornea : a review of refractive surgery complications and new prospects for therapy. Cornea 2005;24:509–22.

[36] Azar G, Doan S, Cochereau I, Gabison EE. Management of post-LASIK recurrent epithelial ingrowth with flap melting using annular amniotic membrane graft. J Cataract Refract Surg 2010;36:2207–8.

[37] Henry CR, Canto AP, Galor A, et al. Epithelial ingrowth after LASIK : clinical characteristics, risk factors, and visual outcomes in patients requiring flap lift. J Refract Surg Thorofare NJ 1995;2012(28):488–92.

[38] Wilde C, Messina M, Dua HS. Management of recurrent epithelial ingrowth following laser in situ keratomileusis with mechanical debridement, alcohol, mitomycin-C, and fibrin glue. J Cataract Refract Surg 2017;43:980–4.

[39] Taneri S, Koch JM, Melki SA, Azar DT. Mitomycin-C assisted photorefractive keratectomy in the treatment of buttonholed laser in situ keratomileusis flaps associated with epithelial ingrowth. J Cataract Refract Surg 2005;31:2026–30.

[40] Kymionis G, Ide T, Yoo S. Flap amputation with phototherapeutic keratectomy (PTK) and adjuvant mitomycin C for severe post-LASIK epithelial ingrowth. Eur J Ophthalmol 2009;19:301–3.

[41] Chang YM, Liang CM, Weng TH, et al. Mitomycin C for the prevention of corneal haze in photorefractive keratectomy : a meta-analysis and trial sequential analysis. Acta Ophthalmol (Copenh) 2021;99:652–62.

[42] Santhiago MR, Netto MV, Wilson SE. Mitomycin C : biological effects and use in refractive surgery. Cornea 2012;31:311–21.

[43] Netto MV, Mohan RR, Sinha S, et al. Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. J Refract Surg Thorofare NJ 1995;2006(22):562–74.

[44] Hjortdal JØ, Møller-Pedersen T, Ivarsen A, Ehlers N. Corneal power, thickness, and stiffness : results of a prospective randomized controlled trial of PRK and LASIK for myopia. J Cataract Refract Surg 2005;31:21–9.

[45] Hersh PS, Brint SF, Maloney RK, et al. Photorefractive keratectomy versus laser in situ keratomileusis for moderate to high myopia. A randomized prospective study. Ophthalmology 1998;105:1512–22. discussion 1522-3.

[46] Mifflin MD, Betts BS, Nguyen J, Pouly S. High myopic photorefractive keratectomy outcomes with the Alcon Wavelight® EX500 excimer laser. Clin Ophthalmol Auckl NZ 2018;12:1041–8.
[47] Sia RK, Ryan DS, Edwards JD, et al. The U.S. Army Surface Ablation Study : comparison of PRK, MMC-PRK, and LASEK in moderate to high myopia. J Refract Surg Thorofare NJ 1995;2014(30):256–64.
[48] Diakonis VF, Kankariya VP, Kymionis GD, et al. Long term followup of photorefractive keratectomy with adjuvant use of mitomycin C. J Ophthalmol 2014;2014, 821920.
[49] Shah RA, Wilson SE. Use of mitomycin-C for phototherapeutic keratectomy and photorefractive keratectomy surgery. Curr Opin Ophthalmol 2010;21:269–73.
[50] Weiner MJ, Trentacoste J, Pon DM, Albert DM. Epithelial downgrowth : a 30-year clinicopathological review. Br J Ophthalmol 1989;73:6–11.
[51] Vargas LG, Vroman DT, Solomon KD, et al. Epithelial downgrowth after clear cornea phacoemulsification : report of two cases and review of the literature. Ophthalmology 2002;109:2331–5.
[52] Mihail Z, Alina-Cristina S, Speranta S. Retrocorneal membranes after penetrating keratoplasty. Romanian J Ophthalmol 2015;59:230–4.
[53] Koenig SB, Covert DJ. Epithelial ingrowth after Descemet-stripping automated endothelial keratoplasty. Cornea 2008;27:727–9.
[54] Theophanous CN, Avdagic E, Farooq AV, et al. Management of severe epithelial versus fibrous downgrowth following trabeculectomy : case report and literature review. Am J Ophthalmol Case Rep 2021;23, 101183.
[55] Ni N, Goldberg MA, Eagle RC, et al. Epithelial downgrowth after intraocular surgery treated with intracameral 5-fluorouracil. Case Rep Ophthalmol Med 2015;2015, 325485.
[56] Abdollah Z, Mohd Zahidin AZ, Ahem A, et al. Successful treatment of epithelial downgrowth with endoscopic photocoagulation and intracameral 5-fluorouracil after prolonged limbal wound leak. Int J Ophthalmol 2018;11:703–4.
[57] Lai MM, Haller JA. Resolution of epithelial ingrowth in a patient treated with 5-fluorouracil. Am J Ophthalmol 2002;133:562–4.
[58] Shaikh AA, Damji KF, Mintsioulis G, et al. Bilateral epithelial downgrowth managed in one eye with intraocular 5-fluorouracil. Arch Ophthalmol Chic Ill 1960;2002(120):1396–8.
[59] Wong RK, Greene DP, Shield DR, et al. 5-Fluorouracil for epithelial downgrowth after Descemet stripping automated endothelial keratoplasty. Cornea 2013;32:1610–2.
[60] Yu CS, Chiu SI, Tse RKK. Treatment of cystic epithelial downgrowth with intralesional administration of mitomycin C. Cornea 2005;24:884–6.
[61] Grover DS, Kornmann HL, Fellman RL. Historical considerations and innovations in the perioperative use of mitomycin C for glaucoma filtration surgery and bleb revisions. J Glaucoma 2020;29:226–35.
[62] Kumar V, Ali MJ, Ramachandran C. Effect of mitomycin-C on contraction and migration of human nasal mucosa fibroblasts : implications in dacryocystorhinostomy. Br J Ophthalmol 2015;99:1295–300.
[63] Cheng S, Feng Y, Xu L, et al. Efficacy of mitomycin C in endoscopic dacryocystorhinostomy : a systematic review and meta-analysis. PLoS One 2013;8, e62737.
[64] Chen PL, Chen WY, Lu DW. Evaluation of mitomycin C in reducing postoperative adhesions in strabismus surgery. J Ocul Pharmacol 2005;21:406–10.
[65] Mahindrakar A, Tandon R, Menon V, et al. Effectiveness of mitomycin C in reducing reformation of adhesions following surgery for restrictive strabismus. J Pediatr Ophthalmol Strabismus 2001;38:131–5. quiz 172-3.